SHJBF OTC
Shanghai Junshi Biosciences Co., Ltd.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +8.8%
1Y: -14.8%
3Y: -40.2%
$3.35
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$2.4B
+24.9% ▲
5Y CAGR: +8.8%
Gross Profit
$1.8B
+21.5% ▲
5Y CAGR: +7.6%
Operating Income
-$909M
+30.1% ▲
Net Income
-$852M
+33.6% ▲
EPS (Diluted)
$-0.84
+35.4% ▲
EBITDA
-$599M
+41.5% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $4.0B | $1.5B | $1.5B | $1.9B | $2.4B |
| YoY Growth | +152.4% | -63.9% | +3.4% | +29.7% | +24.9% |
| Cost of Revenue | $1.3B | $526M | $667M | $499M | $665M |
| Gross Profit | $2.8B | $927M | $835M | $1.4B | $1.8B |
| Gross Margin | 68.7% | 63.8% | 55.6% | 74.4% | 72.3% |
| R&D Expenses | $2.1B | $2.4B | $1.9B | $1.3B | $0 |
| SG&A Expenses | $1.4B | $1.3B | $1.4B | $1.5B | $0 |
| Operating Expenses | $3.4B | $3.7B | $3.3B | $2.7B | $2.7B |
| Operating Income | -$593M | -$2.8B | -$2.5B | -$1.3B | -$909M |
| Operating Margin | -14.7% | -189.3% | -163.2% | -66.7% | -37.4% |
| Interest Expense | $22M | $29M | $29M | $51M | $74M |
| Income Before Tax | -$593M | -$2.7B | -$2.5B | -$1.4B | -$995M |
| Tax Expense | $136M | -$93M | $44M | $23M | -$14M |
| Net Income | -$719M | -$2.4B | -$2.3B | -$1.3B | -$852M |
| Net Margin | -17.9% | -164.2% | -151.9% | -65.8% | -35.0% |
| EPS (Diluted) | $-0.81 | $-2.60 | $-2.32 | $-1.30 | $-0.84 |
| EBITDA | -$308M | -$2.4B | -$2.2B | -$1.0B | -$599M |
| Shares Outstanding | 893M | 917M | 984M | 985M | 1.01B |